• Jennerex Inc., of San Francisco, said it treated the first patient in a Phase I/II trial of JX-594, an engineered oncolytic virus, in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for Erbitux (cetuximab, Eli Lilly and Co.) The two-arm, dose-escalation study, expected to enroll up to 42 patients, will test the drug as a monotherapy and in combination with irinotecan, and endpoints will include safety, dose optimization and tumor responses as measured by RECIST and Choi criteria.